ATE540044T1 - Lpa-rezeptor-agonisten und antagonisten und verwendungsverfahren dafür - Google Patents

Lpa-rezeptor-agonisten und antagonisten und verwendungsverfahren dafür

Info

Publication number
ATE540044T1
ATE540044T1 AT04809934T AT04809934T ATE540044T1 AT E540044 T1 ATE540044 T1 AT E540044T1 AT 04809934 T AT04809934 T AT 04809934T AT 04809934 T AT04809934 T AT 04809934T AT E540044 T1 ATE540044 T1 AT E540044T1
Authority
AT
Austria
Prior art keywords
treating
methods
lpa
antagonists
lpa receptor
Prior art date
Application number
AT04809934T
Other languages
English (en)
Inventor
Duane Miller
Gabor Tigyi
Gangadhar Durgam
Tamas Virag
Michelle Walker
Ryoko Tsukahara
Original Assignee
Univ Tennessee Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34421820&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE540044(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Tennessee Res Foundation filed Critical Univ Tennessee Res Foundation
Application granted granted Critical
Publication of ATE540044T1 publication Critical patent/ATE540044T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/11—Esters of phosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/05—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/113—Esters of phosphoric acids with unsaturated acyclic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/1653—Esters of thiophosphoric acids with arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/17—Esters of thiophosphoric acids with hydroxyalkyl compounds without further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C07F9/173—Esters of thiophosphoric acids with unsaturated acyclic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04809934T 2003-10-09 2004-10-12 Lpa-rezeptor-agonisten und antagonisten und verwendungsverfahren dafür ATE540044T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50997103P 2003-10-09 2003-10-09
PCT/US2004/033601 WO2005032494A2 (en) 2003-10-09 2004-10-12 Lpa receptor agonists and antagonists and methods of use

Publications (1)

Publication Number Publication Date
ATE540044T1 true ATE540044T1 (de) 2012-01-15

Family

ID=34421820

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04809934T ATE540044T1 (de) 2003-10-09 2004-10-12 Lpa-rezeptor-agonisten und antagonisten und verwendungsverfahren dafür

Country Status (9)

Country Link
US (3) US7217704B2 (de)
EP (3) EP2433946B1 (de)
JP (1) JP5048333B2 (de)
KR (2) KR101216266B1 (de)
AT (1) ATE540044T1 (de)
AU (1) AU2004278042B2 (de)
CA (1) CA2540809C (de)
DK (1) DK1678096T3 (de)
WO (1) WO2005032494A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270634A1 (en) * 2005-05-06 2006-11-30 Miller Duane D Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors
EP1906972B1 (de) * 2005-07-19 2013-09-11 The University of Tennessee Research Foundation LPA2-Rezeptoragonist zur Behandlung von Durchfall
EP2099469A4 (de) * 2006-11-15 2013-02-27 Univ Tennessee Res Foundation Strahlungsschutz und behandlung für gammastrahlenexposition
EP3434259A1 (de) 2007-05-04 2019-01-30 Marina Biotech, Inc. Aminosäurelipide und verwendungen davon
EP2262371B1 (de) * 2008-03-03 2014-01-01 Rxbio, Inc. Lpa-rezeptoragonisten und -antagonisten
US8802706B2 (en) 2008-08-07 2014-08-12 Nagasaki University Method for treating fibromyalgia
ES2432386T3 (es) 2008-11-05 2013-12-03 Clariant Finance (Bvi) Limited Procedimiento para la preparación de ácidos, ésteres y sales dialquilfosfínicos mono-carboxi-funcionalizados por medio de alcoholes alílicos/acroleínas y su uso
ES2525550T3 (es) 2008-11-07 2014-12-26 Clariant Finance (Bvi) Limited Procedimiento para la preparación de ácidos, ésteres y sales dialquilfosfínicos mediante derivados del ácido acrílico y su uso
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
DE102008060035A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
CN103724372B (zh) 2008-12-18 2017-03-01 科莱恩金融(Bvi)有限公司 亚乙基二烷基次膦酸、亚乙基二烷基次膦酸酯和亚乙基二烷基次膦酸盐的用途
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
DE102008063642A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
DE102008063627A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) * 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
JP6039559B2 (ja) 2010-09-02 2016-12-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｌｐａ受容体アンタゴニストとしてのピラゾロピリジノン誘導体
US9034820B2 (en) 2011-03-14 2015-05-19 Hsinyu Lee Method and composition for modulating erythropoiesis
CN103596947A (zh) 2011-04-05 2014-02-19 艾米拉医药股份有限公司 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物
EP2744807A4 (de) 2011-08-15 2015-03-04 Intermune Inc Verbindungen als lysophosphatidsäure-rezeptorantagonisten
JP2015084649A (ja) * 2012-01-06 2015-05-07 国立大学法人東北大学 リゾリン脂質シグナル制御による幹細胞の維持増殖培養法
WO2015102856A1 (en) * 2013-12-30 2015-07-09 Rxbio Inc. Crystalline salts of (z)-o-octadec-9-en-1-yl o,o-dihydrogen phosphorothioate
WO2017011457A1 (en) * 2015-07-12 2017-01-19 The University Of Tennessee Research Foundation Compositions and methods for protecting colonic epithelial barrier function
IL289951B2 (en) * 2019-07-30 2025-10-01 Taisho Pharmaceutical Co Ltd Urea compound as an LPA1 receptor antagonist
JP7859068B2 (ja) * 2021-01-28 2026-05-15 大正製薬株式会社 Ｌｐａ１受容体を拮抗するウレア化合物を有効成分として含有する医薬

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2735832A (en) * 1956-02-21 Bx s sx p px s sx e e
US5565439A (en) * 1992-11-24 1996-10-15 The Procter & Gamble Company Methods of using lysophosphatidic acid for treating hyperproliferative conditions
US6495532B1 (en) * 1997-03-19 2002-12-17 Sky High, Llc Compositions containing lysophosphotidic acids which inhibit apoptosis and uses thereof
EP1024812B1 (de) * 1997-03-19 2007-01-24 Sky High, LLC Lysophophasäure enthaltende zusammensetzungen die die apoptose hemmen und deren verwendung
WO1999047101A2 (en) * 1998-03-18 1999-09-23 Lxr Biotechnology, Inc. Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof
US6852213B1 (en) * 1999-09-15 2005-02-08 Nalco Energy Services Phosphorus-sulfur based antifoulants
CA2402038C (en) * 2000-03-17 2011-03-15 The University Of Tennessee Research Corporation Lpa receptor agonists and antagonists and methods of use
US20030130237A1 (en) * 2000-03-17 2003-07-10 Miller Duane D. LPA receptor agonists and antagonists and methods of use

Also Published As

Publication number Publication date
EP1678096B1 (de) 2012-01-04
EP2481743A1 (de) 2012-08-01
EP2433946B1 (de) 2016-04-20
CA2540809A1 (en) 2005-04-14
WO2005032494A3 (en) 2005-09-15
EP1678096A4 (de) 2007-04-18
DK1678096T3 (da) 2012-04-23
AU2004278042A1 (en) 2005-04-14
EP1678096A2 (de) 2006-07-12
CA2540809C (en) 2013-09-24
KR101216266B1 (ko) 2012-12-28
JP5048333B2 (ja) 2012-10-17
EP2481743B1 (de) 2017-03-22
WO2005032494A2 (en) 2005-04-14
KR20060118469A (ko) 2006-11-23
AU2004278042B2 (en) 2012-02-09
US7217704B2 (en) 2007-05-15
KR20120120385A (ko) 2012-11-01
KR101390040B1 (ko) 2014-04-29
JP2007508324A (ja) 2007-04-05
EP2433946A1 (de) 2012-03-28
US20080090783A1 (en) 2008-04-17
US20060009507A1 (en) 2006-01-12
US20120135967A1 (en) 2012-05-31
US7947665B2 (en) 2011-05-24

Similar Documents

Publication Publication Date Title
DK1678096T3 (da) LPA-receptoragonister og -antagonister og anvendelsesfremgangsmåder
DK1263752T3 (da) LPA-receptoragonister og -antagonister og fremgangsmåde til anvendelse heraf
BR0306988A (pt) Piridazinonas substituìdas como inibidores de p38
CY1118768T1 (el) Ετεροκυκλικοι ρυθμιστες μεταφορεων κασετας συνδεσης atp
PA8550101A1 (es) Derivados de benzamida tiazol y composiciones farmacéuticas para inhibir la proliferación de células, y métodos para su utilización
LTPA2016016I1 (lt) Azetinidai kaip mek inhibitoriai, skirti proliferacinių ligų gydymui
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
EA200801291A1 (ru) Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
CY1115489T1 (el) ΠΑΡΑΛΛΑΓΜΑΤΑ ΠΡΟΕΡΧΟΜΕΝΑ ΑΠΟ ActRIIB ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
UY29458A1 (es) Heterociclos sustituidos y usos de los mismos
TW200638934A (en) Heteroaryl compounds as P2Y1 receptor inhibitors
UA83311C2 (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MA28279A1 (fr) Derives d'indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
TR200003801T2 (tr) Acı hafifletmek için deri üstü kompozisyonlar ve yöntemler
TW200608966A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
UA83917C2 (en) 3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
WO2003024402A3 (en) Lpa receptor agonists and antagonists and methods of use
BR0307903A (pt) derivados de arilsulfona
IL178727A0 (en) Tetrahydropyridothiophene derivatives and pharmaceutical compositions containing the same
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
BRPI0416994A (pt) inibidores de proteìna cinase com base em indolinona avançada
DE602005015203D1 (de) Neue piperidinsubstituierte diaminothiazole